company background image
DCPH

Deciphera Pharmaceuticals NasdaqGS:DCPH Stock Report

Last Price

US$16.71

Market Cap

US$1.3b

7D

-1.8%

1Y

104.8%

Updated

07 Feb, 2023

Data

Company Financials +

Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Stock Report

Mkt Cap: US$1.3b

DCPH Stock Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.

DCPH fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Deciphera Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Deciphera Pharmaceuticals
Historical stock prices
Current Share PriceUS$16.71
52 Week HighUS$22.76
52 Week LowUS$6.51
Beta0.69
1 Month Change-22.67%
3 Month Change10.30%
1 Year Change104.78%
3 Year Change-75.73%
5 Year Change-42.22%
Change since IPO-5.33%

Recent News & Updates

Recent updates

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%

Feb 11
Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Feb 05
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera to expand geographic reach and clinical potential of ripretinib

Jan 11

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price

Dec 15
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price

Deciphera completes enrollment in late-stage study of ripretinib in GIST patients

Nov 30

Shareholder Returns

DCPHUS BiotechsUS Market
7D-1.8%-0.8%0.9%
1Y104.8%3.9%-10.9%

Return vs Industry: DCPH exceeded the US Biotechs industry which returned 4.3% over the past year.

Return vs Market: DCPH exceeded the US Market which returned -9.6% over the past year.

Price Volatility

Is DCPH's price volatile compared to industry and market?
DCPH volatility
DCPH Average Weekly Movement9.8%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: DCPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: DCPH's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003280Steve Hoerterhttps://www.deciphera.com

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.

Deciphera Pharmaceuticals, Inc. Fundamentals Summary

How do Deciphera Pharmaceuticals's earnings and revenue compare to its market cap?
DCPH fundamental statistics
Market CapUS$1.26b
Earnings (TTM)-US$221.39m
Revenue (TTM)US$121.89m

10.3x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DCPH income statement (TTM)
RevenueUS$121.89m
Cost of RevenueUS$198.53m
Gross Profit-US$76.64m
Other ExpensesUS$144.75m
Earnings-US$221.39m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 07, 2023

Earnings per share (EPS)-2.94
Gross Margin-62.88%
Net Profit Margin-181.63%
Debt/Equity Ratio0%

How did DCPH perform over the long term?

See historical performance and comparison